IXICO plc Stock

Equities

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:09 2024-06-14 EDT 5-day change 1st Jan Change
6.875 GBX 0.00% Intraday chart for IXICO plc -1.79% -45.00%

Financials

Sales 2024 * 5.2M 6.6M 9.06M Sales 2025 * - Capitalization 3.32M 4.22M 5.79M
Net income 2024 * -2M -2.54M -3.49M Net income 2025 * - EV / Sales 2024 * 0.37 x
Net cash position 2024 * 1.4M 1.78M 2.44M Net cash position 2025 * - 0 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.25 x
P/E ratio 2025 *
-
Employees 89
Yield 2024 *
-
Yield 2025 *
-
Free-Float 51.17%
More Fundamentals * Assessed data
Dynamic Chart
1 week-1.79%
Current month-1.79%
1 month-6.78%
3 months-5.17%
6 months-48.11%
Current year-45.00%
More quotes
1 week
6.50
Extreme 6.5
7.18
1 month
6.50
Extreme 6.5
7.75
Current year
6.35
Extreme 6.35
13.50
1 year
6.35
Extreme 6.35
21.00
3 years
6.35
Extreme 6.35
92.00
5 years
6.35
Extreme 6.35
127.00
10 years
6.35
Extreme 6.35
127.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 17-02-05
Director of Finance/CFO 47 19-05-30
Chairman 59 13-10-13
Members of the board TitleAgeSince
Chairman 59 13-10-13
Director/Board Member 49 16-09-15
Director/Board Member 60 23-10-04
More insiders
Date Price Change Volume
24-06-14 6.875 0.00% 185,023
24-06-13 6.875 0.00% 0
24-06-12 6.875 -1.79% 20,810
24-06-11 7 0.00% 5,714
24-06-10 7 0.00% 84,500

Delayed Quote London S.E., June 14, 2024 at 11:35 am

More quotes
IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Annual profits - Rate of surprise